The Stem Cell Marker CD133 Associates with Enhanced Colony Formation and Cell Motility in Colorectal Cancer
Open Access
- 19 May 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (5) , e10714
Abstract
CD133 is a membrane molecule that has been, controversially, reported as a CSC marker in colorectal cancer (CRC). In this study, we sought to clarify the expression and role of CD133 in CRC. Initially the size of the CD133−expressing (CD133+) population in eight well-described CRC cell lines was measured by flow cytometry and was found to range from 0% to >95%. The cell line HT29 has a CD133+ population of >95% and was chosen for functional evaluation of CD133 after gene knockdown by RNA interference. A time course assay showed that CD133 inhibition had no significant effect on cell proliferation or apoptosis. However, CD133 knockdown did result in greater susceptibility to staurosporine-induced apoptosis (p = 0.01) and reduction in cell motility (p<0.04). Since gene knockdown may cause “off-target” effects, the cell line SW480 (which has a CD133+ population of 40%) was sorted into pure CD133+ and CD133− populations to allow functional comparison of isogenic populations separated only by CD133 expression. In concordance with the knockdown experiments, a time course assay showed no significant proliferative differences between the CD133+/CD133− populations. Also greater resistance to staurosporine-induced apoptosis (p = 0.008), greater cell motility (p = 0.03) and greater colony forming efficiency was seen in the CD133+ population than the CD133− population in both 2D and 3D culture (p<0.0001 and p<0.003 respectively). Finally, the plasticity of CD133 expression in tumour cells was tested. Quantitative PCR analysis showed there was transcriptional repression in the CD133− population of SW480. Prolonged culture of a pure CD133− population resulted in re-emergence of CD133+ cells. We conclude that CD133 expression in CRCs is associated with some features attributable to stemness and that there is plasticity of CD133 expression. Further studies are necessary to delineate the mechanistic basis of these features.Keywords
This publication has 32 references indexed in Scilit:
- The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancerThe Journal of Pathology, 2009
- C‐terminal Tensin‐like (CTEN) is an oncogene which alters cell motility possibly through repression of E‐cadherin in colorectal cancerThe Journal of Pathology, 2008
- Attributes of adult stem cellsThe Journal of Pathology, 2008
- Abnormal DNA Methylation ofCD133in Colorectal and Glioblastoma TumorsCancer Research, 2008
- The Stem Cell-Associated Antigen CD133 (Prominin-1) Is a Molecular Therapeutic Target for Metastatic MelanomaStem Cells, 2008
- Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cellsAmerican Journal of Physiology-Renal Physiology, 2008
- CD133 expression is not restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumorsJournal of Clinical Investigation, 2008
- Brca1 breast tumors contain distinct CD44+/CD24- and CD133+cells with cancer stem cell characteristicsBreast Cancer Research, 2008
- AC133-2, a Novel Isoform of Human AC133 Stem Cell AntigenJournal of Biological Chemistry, 2002
- The Human AC133 Hematopoietic Stem Cell Antigen Is also Expressed in Epithelial Cells and Targeted to Plasma Membrane ProtrusionsJournal of Biological Chemistry, 2000